Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 12

UroToday

ASCO GU 2023: Niraparib with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Homologous Recombination Repair Gene Alterations: Second Interim Analysis of MAGNITUDE -

ASCO GU 2023 interim analysis of MAGNITUDE, combination of niraparib and abiraterone acetate/prednisone in patients with metastatic castrate-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.

  • 123456 Profile photo of Madelyn
    Catherine Marshall

    MAGTIDUTE study – niraparib + abiraterone in patients w/mCRPC and HRD mutations. Improvement in progression free survival…too early to know about overall survival benefit.

Read the full article here
See more from Catherine Marshall